Study of Nicotine Replacement Therapy in Pregnancy
Study Details
Study Description
Brief Summary
The overall objective of this study is to assess the effectiveness of NRT (Nicoderm patches) plus counselling treatment in women in the second and third trimester of pregnancy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Smoking during pregnancy is a major public health issue, causing miscarriages, prematurity, intrauterine growth retardation, stillbirth, and the Sudden Infant Death Syndrome (SIDS). It is estimated that 25-40% of pregnant smokers try to stop smoking on their own upon learning that they are pregnant. While pregnancy is often a strong motivator for smoking cessation, many nicotine-dependent women cannot quit smoking. The most important factor underlying the inability to quit smoking is strong dependence on a certain level nicotine, which is unique in every individual.
Several publications have shown that the use of the nicotine patch during the second and third trimesters is not associated with maternal or fetal compromise. More importantly, nicotine replacement therapy (NRT) during pregnancy exposes the fetus to lower levels of nicotine than smoking cigarettes does and, moreover, eliminates exposure to numerous other toxic substances.
Presently, counselling is the standard mode of treatment for the pregnant patients willing to quit smoking. Since pharmacologic smoking cessation therapies have been shown to increase significantly up to doubling a successful quitting rate when used in adjunction to brief physician counselling, the use of an appropriate dose of such agents is essential.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1
|
Drug: Nicoderm patches
Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
|
| Active Comparator: 2
|
Other: Counselling
Women in this arm of the study will receive standard counseling only.
|
Outcome Measures
Primary Outcome Measures
- To assess the effectiveness of NRT (Nicoderm patches) at doses of 14 mg/day or 21 mg/day plus counselling treatment [6 months]
Secondary Outcome Measures
- To compare the effectiveness of counseling and NRT at doses of 14 mg/day or 21 mg/day with counselling alone. [6 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women who smoke
-
Pregnant women after 12 weeks gestation, confirmed by ultrasound
-
On the day of the recruitment, women will be at least 18 years old and no older than 40 years old
-
Agree to sign consent form and participate in all aspects of the follow-up
Exclusion Criteria:
-
Women who refuse to participate in the study/sign a written consent
-
Women with insufficient English language skills to understand the questionnaires and assessment material
-
Women with multiple pregnancy
-
Women with confirmed cardiac pathology
-
Women who receive concurrent treatment with Bupropion
-
Congenital malformations visualized by ultrasound
-
Objection from the physician caring for the woman to her participation
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- The Hospital for Sick Children
Investigators
- Principal Investigator: Gideon Koren, MD, The Hospital for Sick Children
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1000010740